Ann: CEO presentation to Broker Meets Biotech - Perth, page-40

I think our lack of good data was a problem for the EU.

Now we should have fda approved, blinded data and lots of it.

The tis timing was unfortunate as there had just been a case of some people dying on a clinical trial - so everybody was being extra cautious. So the approval buck was passed around by the bma, the eu and others.

As for stale holders - good clinical data will clean away them in no time. New money doesn't care about the past imho.